HSD17B10

Across TCGA pan-cancer cohorts, HSD17B10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HSD17B10 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSD17B10 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HSD17B10 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where HSD17B10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.499	0.321	.013	18	view →
CCRCC	OS	Tertile	All	1.000	0.758	.049	5	view →
UCEC	OS	Median	All	0.857	0.965	.034	4	view →
HNSC	OS	Tertile	IV	0.637	0.891	.037	3	view →
LSCC	OS	Median	All	0.752	0.861	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HSD17B10–PDAC (DFS)

Open the PDAC breakdown →